{"id":"lerodalcibep","rwe":[{"pmid":"41771767","year":"2026","title":"Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review.","finding":"","journal":"British journal of pharmacology","studyType":"Clinical Study"},{"pmid":"41730058","year":"2006","title":"Lerodalcibep.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"41616414","year":"2026","title":"From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies.","finding":"","journal":"Pharmacological reviews","studyType":"Clinical Study"},{"pmid":"41550128","year":"2026","title":"Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis.","finding":"","journal":"International journal of cardiology. Cardiovascular risk and prevention","studyType":"Clinical Study"},{"pmid":"41089781","year":"2025","title":"Lerodalcibep: Another Crucial Addition to the Dyslipidaemia Arsenal.","finding":"","journal":"Reviews in cardiovascular medicine","studyType":"Clinical Study"}],"_fda":{"id":"593f8f9d-235b-4753-8843-4d7e6d6d5365","set_id":"422f8b04-6ce8-4e64-a0a9-0ccc9a4a5860","openfda":{"unii":["1PHP3QG5PZ"],"route":["SUBCUTANEOUS"],"rxcui":["2729467","2729474"],"spl_id":["593f8f9d-235b-4753-8843-4d7e6d6d5365"],"brand_name":["LEROCHOL"],"spl_set_id":["422f8b04-6ce8-4e64-a0a9-0ccc9a4a5860"],"package_ndc":["84685-300-01"],"product_ndc":["84685-300"],"generic_name":["LERODALCIBEP-LIGA"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["LERODALCIBEP"],"manufacturer_name":["LIB Therapeutics, Inc."],"application_number":["BLA761427"],"is_original_packager":[true]},"version":"2","pregnancy":["8.1 Pregnancy Risk Summary Discontinue LEROCHOL when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. LEROCHOL increases LDL-C uptake and lowers LDL-C levels in the circulation, thus decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, LEROCHOL may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology ( 12.1 )]. In addition, treatment of hypercholesterolemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia for most patients. Available data from clinical trials on LEROCHOL use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, there were no adverse developmental effects observed when pregnant monkeys were administered lerodalcibep-liga subcutaneously during organogenesis and through to parturition at doses up to 100 mg/kg/week [up to 119-fold the exposure at the maximum recommended human dose (MRHD) of 300 mg every month]. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In cynomolgus monkeys, no effects on embryo-fetal or postnatal development (up to 6 months of age) were observed when lerodalcibep-liga was dosed during organogenesis and through parturition at 30 and 100 mg/kg subcutaneously once weekly (exposures up to 119-fold the MRHD by AUC). An assessment of immune function in the infants showed no treatment-related adverse effects. Measurable lerodalcibep-liga serum concentrations were observed in the infant monkeys with infant serum concentrations approximately 2 to 7% of maternal serum concentrations on postnatal days 14, 21 and 28, indicating that lerodalcibep-liga has the potential to be transmitted from the mother to the developing fetus."],"description":["11 DESCRIPTION Lerodalcibep-liga is a recombinant fusion protein therapeutic agent comprised of a proprotein convertase subtilisin/kexin type 9 (PCSK9)-binding domain and human serum albumin (HSA). Lerodalcibep-liga is produced in genetically engineered mammalian (Chinese hamster ovary) cells as a single protein with an approximate molecular weight of 77 kDa. LEROCHOL (lerodalcibep-liga) injection is a clear to slightly opalescent, brownish-yellow to amber, sterile, preservative-free solution for subcutaneous injection. Each single-dose prefilled syringe contains 1.2 mL of lerodalcibep-liga (300 mg), histidine (3.07 mg), L-histidine monohydrochloride (0.88), polysorbate 80 (0.24 mg), sodium chloride (10.52), and Water for Injection. The pH is 6.8."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied LEROCHOL (lerodalcibep-liga) injection 300 mg/1.2 mL (250 mg/mL) is supplied as a single-dose prefilled syringe for subcutaneous injection and is a clear to slightly opalescent, brownish-yellow to amber, sterile, preservative-free solution. LEROCHOL is supplied in cartons containing one single-dose prefilled syringe (NDC 84685-300-01). Storage and Handling Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake. If needed, LEROCHOL may be kept at room temperature up to 25°C (77°F) in the original carton and must be used within 3 months of being removed from the refrigerator. If not used within 3 months, discard LEROCHOL. Do not use beyond the expiration date on the container or package."],"geriatric_use":["8.5 Geriatric Use Of the 1,631 patients treated with LEROCHOL 300 mg in clinical trials, 687 (42%) patients were 65 years of age and older, while 198 (12%) patients were 75 years of age or older. No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger adult patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of LEROCHOL in pediatric patients have not been established. Clinical trials of LEROCHOL in pediatric patients with HeFH have not been conducted. Effectiveness of LEROCHOL was not demonstrated in a 24-week, randomized, open-label, active-controlled trial (NCT04034485) in 19 pediatric patients aged 10 to 17 years with homozygous familial hypercholesterolemia (HoFH)."],"effective_time":"20251217","clinical_studies":["14 CLINICAL STUDIES The efficacy of LEROCHOL was evaluated in three randomized, double-blind, placebo-controlled trials that enrolled 2,017 adults with HeFH, clinical ASCVD, or increased risk for ASCVD, who were on a stable low-fat, low-cholesterol diet and maximally tolerated statin therapy and who required additional LDL-C lowering. Primary Hypercholesterolemia Trial 1 (NCT04797247) and Trial 2 (NCT04806893) were both multicenter, double-blind, randomized, placebo-controlled 52-week trials in which 1,844 adults with ASCVD or at increased risk for ASCVD events were randomized 2:1 to receive subcutaneous injections of either LEROCHOL 300 mg (n=1,229) or placebo (n=615) every 4 weeks. Patients were stable on a low-fat, low-cholesterol diet, maximally tolerated dose of statin with or without other oral lipid modifying therapy, and required additional LDL-C reduction. Baseline Disease and Demographic Characteristics The mean age in Trial 1 at baseline was 64 years (range: 25 to 90 years), 49% were 65 years or older, 30% were female, 80% were White, 17% were Black or African American, and 3% were Asian; 1.1% identified as Hispanic or Latino ethnicity. Thirty four percent (34%) of patients had diabetes at baseline, 86% established ASCVD, and 14% at increased risk for CVD events. The mean baseline LDL-C was 102 mg/dL. At the time of randomization, 87% of patients were receiving statin therapy and of these 53% were receiving high-intensity statin therapy; 18% were receiving ezetimibe either in combination with a statin or alone. The mean age in Trial 2 at baseline was 65 years (range: 27 to 87 years), 54% were 65 years or older, 45% were female, 78% were White, 18% were Black or African American, and 4% were Asian; 13% identified as Hispanic or Latino ethnicity. Forty-three percent (43%) of patients had diabetes at baseline, 48% established ASCVD, and 52% at increased risk for CVD events. The mean baseline LDL-C was 116 mg/dL. At the time of randomization, 83% of patients were receiving statin therapy and of these, 39% were on high-intensity doses; 17% were receiving ezetimibe either in combination with a statin or alone. Endpoint Results The primary efficacy outcome measure in Trial 1 was the placebo adjusted intent to treat (ITT) analysis of percent change in LDL-C from baseline to Week 52. The difference between the LEROCHOL and placebo group in mean percentage change in LDL-C from baseline to Week 52 was -55% (95% CI: -59.2%, -50.8%; p < 0.0001). For additional results, see Table 3 and Figure 1 . Table 3: Changes in Lipid Parameters in Patients with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD Events on Maximally Tolerated Statin Therapy (Percent Change from Baseline to Week 52 in Trial 1) Abbreviation: ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; n = number of patients randomly assigned to each treatment group; LS Mean= least-squares mean a LDL-C, Total Cholesterol, non-HDL-C and ApoB at Week 52 were missing for 7.5% and 10.4% of patients assigned to placebo and LEROCHOL, respectively. Multiple imputation washout model was implemented for imputing missing values at Week 52. b Least-squares mean from an Analysis of Covariance (ANCOVA) model including treatment as a factor and baseline value as a covariate, assuming unequal variances between groups. c p-value <0.001 for superiority, controlled for Type I error rate. d Not controlled for Type I error rate. Treatment Group LDL-C a Total Cholesterol a Non-HDL-C a ApoB a Placebo (n = 308) -0.1 -0.2 -0.7 +1 LEROCHOL 300mg (n = 614) -55 -31 -46 -39 Difference from placebo (LS Mean) (95% CI) -55 b,c (-59, -51) -31 b,d (-33, -28) -45 b,d (-48, -41) -40 b,d (-44, -37) Figure 1: Mean Percent Change from Baseline in LDL-C Over 52 Weeks in Patients with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD Events on Maximally Tolerated Statin Therapy (Trial 1) The primary efficacy outcome measure in Trial 2 was the percent change in LDL-C from baseline compared to placebo to Week 52. The difference between the LEROCHOL and placebo groups by ITT analysis in mean percentage change in LDL-C from baseline to Week 52 was -50% (95% CI: -54.2%, -45.2%; p < 0.0001). For additional results, see Table 4 and Figure 2 . Table 4: Changes in Lipid Parameters in Patients with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD Events on Maximally Tolerated Statin Therapy (Percent Change from Baseline to Week 52 in Trial 2) Abbreviation: ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; n = number of patients randomly assigned to each treatment group; LS Mean = least-squares mean a LDL-C and non-HDL-C at Week 52 were missing for 10.7% and 11.2% of patients assigned to placebo and LEROCHOL, respectively. Total Cholesterol and ApoB at Week 52 were missing for 10.4% and 11.2% of patients assigned to placebo and LEROCHOL, respectively. Multiple imputation washout model was implemented for imputing missing values at Week 52. b Least-squares mean from an Analysis of Covariance (ANCOVA) model including treatment and CVD status as factors and baseline value as a covariate, assuming unequal variances between groups. c p-value <0.001 for superiority, controlled for Type I error rate. d Not controlled for Type I error rate. Treatment Group LDL-C a Total Cholesterol a Non-HDL-C a ApoB a Placebo (n = 307) +0.3 +1 +1 +2 LEROCHOL 300mg (n = 615) -49 -28 -41 -36 Difference from placebo (LS Mean) (95% CI) l -50 b,c (-54, -45) -29 b,d (-32, -26) -42 b,d (-46, -38) -38 b,d (-42, -35) Figure 2: Mean Percent Change from Baseline in LDL-C Over 52 Weeks in Patients with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD Events on Maximally Tolerated Statin Therapy (Trial 2) Figure 1 Figure 2 Heterozygous Familial Hypercholesterolemia in Adults Trial 3 (NCT04797104) was a multicenter, double-blind, randomized, placebo-controlled 24-week trial in which 478 patients with HeFH were randomized 2:1 to receive subcutaneous injections of either LEROHOL 300 mg (n = 319) or placebo (n = 159) every 4 weeks. Patients were stable on diet, maximally tolerated dose of statin, with or without other oral lipid modifying therapy, and required additional LDL-C reduction. Baseline Disease and Demographic Characteristics The mean age at baseline was 53 years (range: 18 to 80 years), 19% were aged 65 years or older, 52% were female, 87% were White, 8% were Black or African American, and 5% were Asian; 1% identified as Hispanic or Latino ethnicity. Forty-five percent of patients had diabetes at baseline. The mean baseline LDL-C was 150 mg/dL. At the time of randomization, 89% of patients were receiving statin therapy with 67% receiving high-intensity doses, and 49% also on ezetimibe. Endpoint Results The primary efficacy outcome measure in Trial 3 was the percent change in LDL-C from baseline to Week 24. The difference between the LEROCHOL and placebo groups in mean percentage change in LDL-C from baseline to Week 24 was -59% (95% CI: -65.7%, -51.7%; p < 0.0001). For additional results, see Table 5 and Figure 3 . Table 5: Changes in Lipid Parameters in Patients with HeFH, on Maximally Tolerated Statin Therapy (Percent Change from Baseline to Week 24 in Trial 3) Abbreviation: ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; n = number of patients randomly assigned to each treatment group; LS Mean = least-squares mean a LDL-C, Total Cholesterol and non-HDL-C at Week 24 were missing for 3.1% and 2.8% of patients assigned to placebo and LEROCHOL, respectively. ApoB at Week 24 was missing for 3.1% and 3.1% of patients assigned to placebo and LEROCHOL, respectively. Multiple imputation washout model was implemented for imputing missing values at Week 24. b Least-squares mean from an Analysis of Covariance (ANCOVA) model including treatment and CVD status as factors and baseline value as a covariate, assuming unequal variances between groups. c p-value <0.001 for superiority, controlled for Type I error rate. d Not controlled for Type I error rate. Treatment Group LDL-C a Total Cholesterol a Non-HDL-C a ApoB a Placebo (n = 159) + 8 +5 +7 +7 LEROCHOL 300mg (n = 319) -51 -32 -44 -37 Difference from placebo (LS Mean) (95% CI) -59 b,c (-66, -52) -37 b,d (-41, -32) -51 b,d (-57, -45) -44 b,d (-49, -39) Figure 3: Mean Percent Change from Baseline in LDL-C Over 24 Weeks in Patients with HeFH on Maximally Tolerated Statin Therapy (Trial 3) Figure"],"pharmacodynamics":["12.2 Pharmacodynamics After subcutaneous administration of 300 mg lerodalcibep-liga every month, greater than 90% suppression of PCSK9 occurs within 24 hours after dosing and is maintained throughout the dosing interval, returning toward baseline during the last 7 to 10 days of the monthly dosing period."],"pharmacokinetics":["12.3 Pharmacokinetics Following a single subcutaneous administration, exposure to lerodalcibep-liga increased in a dose proportional manner over the dose range 75 to 300 mg of lerodalcibep-liga. Lerodalcibep-liga pharmacokinetics were observed at steady state in patients at the approved recommended dosage and are presented as mean (SD), unless otherwise specified. Lerodalcibep-liga maximum concentration (Cmax) is 31.4 (10.2) mcg/mL, and total systemic exposure (AUC0-tau) is 12,600 (5,190) (hrs*mcg/mL) following subcutaneous dose of lerodalcibep-liga 300 mg once every four weeks. Lerodalcibep-liga steady-state is reached following 2 to 3 doses. Lerodalcibep-liga accumulation is approximately 30% at the approved recommended dosage. Absorption The median (min, max) estimated subcutaneous bioavailability of lerodalcibep-liga is 83% (66%, 89%). The median (min, max) time to maximum plasma concentration (Tmax) is 6 days (2, 9 days) at steady state. Distribution Lerodalcibep-liga does not extensively distribute into tissues; the apparent volume of distribution is 5.3 L. Elimination As a protein, lerodalcibep-liga is expected to degrade to small peptides and amino acids. Clearance of free lerodalcibep-liga (CV%) is 0.36 L/day (30%) with an estimated half-life of approximately 10 days. The estimated elimination rate of lerodalcibep-liga (CV%) bound to PCSK9 is 0.47 L/day (22%) which corresponds to a half-life of approximately 1.5 days. Specific Populations No clinically significant differences in the pharmacokinetics of LEROCHOL were observed based on age (21 to 78 years), body weight, sex, race, mild (eGFR 60 to 89 mL/min) or moderate (eGFR 30 to 59 mL/min) renal impairment, or mild (total bilirubin 1.0 to 1.5 upper limit of normal or aspartate aminotransaminase greater than the upper limit of normal) or moderate (total bilirubin 1.5 to 3.0 upper limit of normal) hepatic impairment. The effect of severe renal impairment (eGFR less than 30 mL/min) or severe hepatic impairment on LEROCHOL pharmacokinetics is unknown. Drug Interaction Studies No formal clinical drug interaction studies have been performed."],"adverse_reactions":["6 ADVERSE REACTIONS Common adverse reactions occurring in ≥1% of patients treated with LEROCHOL were injection site reactions, nasopharyngitis, diarrhea, nausea and peripheral edema. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact LIB Therapeutics, Inc. at 1-877-2-LEROCHOL or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Adults with Primary Hypercholesterolemia Adverse Reactions in Two Pooled 52-week Controlled Trials In two pooled 52-week, double-blind, randomized, placebo-controlled trials (Trials 1 and 2), 1,229 patients received 300 mg of LEROCHOL subcutaneously every 4 weeks [see Clinical Studies ( 14 )] . The mean age was 64 years (range 25 to 90 years), 52% were 65 years of age or older, 37% female, 79% White, 18% Black or African American, 4% Asian; 7% identified as Hispanic or Latino ethnicity. At baseline, 9% of patients had a diagnosis of HeFH, 74% had established atherosclerotic cardiovascular disease (ASCVD), and 26% were at increased risk for ASCVD. Adverse reactions reported in at least 2% of LEROCHOL-treated patients and more frequently than in placebo-treated patients are shown in Table 1 . Adverse reactions led to treatment discontinuation in 4% of LEROCHOL-treated patients and placebo-treated patients. The most frequent adverse reaction leading to treatment discontinuation was injection site reactions, with a higher frequency in the LEROCHOL-treated group compared to placebo-treated patients (1% vs. 0%). Table 1: Adverse Reactions Occurring in ≥2% of LEROCHOL-treated Patients with Hypercholesterolemia and > 1% More Frequently than Placebo-treated Patients in Two Pooled 52-Week Trials (Trials 1 and 2) a Grouped terms composed of several similar terms Adverse Reaction a LEROCHOL 300 mg (N=1,229) % Placebo (N=612) % Nasopharyngitis 15 14 Injection site reactions 12 5 Peripheral edema 2 <1 Adverse Reactions in a 24-Week Controlled Trial In a 24-week, double-blind, randomized, placebo-controlled trial (Trial 3), 318 patients with HeFH received 300 mg of LEROCHOL subcutaneously every 4 weeks [see Clinical Studies ( 14 )]. Adverse reactions reported in at least 2% of LEROCHOL-treated patients, and more frequently than in placebo-treated patients are shown in Table 2 . Table 2: Adverse Reactions Occurring in ≥2% LEROCHOL-treated Patients with HeFH and >1% More Frequently than Placebo-treated Patients at 24 Weeks (Trial 3) Adverse Reaction LEROCHOL 300 mg (N=318) % Placebo (N=159) % a Grouped terms composed of several similar terms Injection site reactions a 18 3 Nasopharyngitis a 13 9 Diarrhea 3 1 Nausea 2 0 Peripheral edema a 2 <1"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels. [see Clinical Pharmacology ( 12.3 )] ."],"instructions_for_use":["INSTRUCTIONS FOR USE LEROCHOL TM [leer-O-call] (lerodalcibep-liga) injection, for subcutaneous use only Single-dose Prefilled Syringe This Instructions for Use contains information on how to inject LEROCHOL. Read and follow these instructions before you start using the LEROCHOL prefilled syringe and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment. Do not use the LEROCHOL prefilled syringe until your healthcare provider has given you instructions on the right way to give an injection. Parts of the Prefilled Syringe (see Figure A ) Figure A Important Information You Need to Know Before Injecting LEROCHOL For subcutaneous injection only (inject under the skin). Do not use LEROCHOL if the seals on the sides of the carton have already been broken. If seals have already been broken, LEROCHOL may have been tampered with, get a new carton. Do not use LEROCHOL if the prefilled syringe is dropped or damaged. Get a new carton. Do not re-cap the prefilled syringe as you may stick yourself or damage the needle. Do not freeze. Safely throw away (dispose of) the used prefilled syringe after the injection is completed (see Step 15. Dispose of used prefilled syringe ). Preparing to Inject LEROCHOL Step 1. Gather the supplies needed to give the injection. Choose a clean, flat surface in a well-lit area. Gather the following supplies and place them on the surface (see Figure B ): Carton containing prefilled syringe Items not included in the carton: Alcohol wipe Cotton ball or gauze Adhesive bandage FDA-cleared Sharps disposal container Figure B Step 2. If refrigerated, let the prefilled syringe warm to room temperature for 30 minutes. Let the carton sit at room temperature for 30 minutes before use (see Figure C ). Keep the prefilled syringe in the carton during warm-up to protect from light. Letting the prefilled syringe warm to room temperature will make the injection more comfortable. Do not use a heat source such as a microwave or warm the carton containing the prefilled syringe any other way. Do not shake the carton. Figure C Step 3. Remove the plastic tray from the carton. Break the seal and open the side of the carton. Do not use LEROCHOL if the seals on the sides of the carton have already been broken. If seals have already been broken, LEROCHOL may have been tampered with, get a new carton. Gently slide the plastic tray containing the prefilled syringe from the carton into the palm of your hand ( Figure D ). Figure D Step 4. Remove the prefilled syringe from the plastic tray. Place the plastic tray on your hand and peel off the paper seal with your other hand (see Figure E ). Turn the plastic tray over and gently press the middle of the tray's back to release the prefilled syringe into the palm of your hand (see Figures F , G and H ). Figure E Figure F Figure G Figure H Do not pick up or pull the prefilled syringe by the plunger rod or gray needle cap. This could damage the syringe. Do not remove the gray needle cap from the prefilled syringe until you are ready to inject. Always hold the prefilled syringe by the syringe barrel. Step 5. Inspect the prefilled syringe. Make sure LEROCHOL appears on the prefilled syringe label. Check the expiration (EXP) date (see Figure I ). Check the prefilled syringe for damage. Do not use and get a new carton if LEROCHOL does not appear on the label, the expiration date has passed, or there are signs of damage. Figure I Step 6. Inspect the medicine. Check the medicine to make sure the liquid is clear to brownish-yellow or amber (see Figure J ). Do not use the prefilled syringe if the liquid is cloudy or contains visible particles. Get a new carton. Figure J Step 7. Wash your hands. Wash your hands with soap and water and dry them thoroughly (see Figure K ). Figure K Step 8. Choose an injection site. Choose an injection site from the following areas (see Figure L ): Stomach area (abdomen) except for the 2-inch (5 cm) area right around your navel (belly button) Front of upper legs (thighs) Back of upper arms (injection by caregiver or healthcare provider only) Do not inject LEROCHOL together with other injectable drugs at the same site. Do not select an area of the skin that is tender, bruised, red, or hard. Avoid areas with scars or stretch marks. Do not inject through clothing. Choose a different site each time you give yourself an injection. If you need to use the same injection site, make sure it is not the same spot on the site you used last time. Figure L Step 9. Clean the injection site. Clean the skin of the injection site with an alcohol wipe (see Figure M ). Do not touch or blow on the injection site again before giving the injection. Let the skin dry before injecting. Figure M Injecting LEROCHOL Step 10. Remove the needle cap. Hold the barrel of the prefilled syringe with the needle facing away from you. Firmly grip the needle cap and pull it straight off (see Figure N ). Do not twist the needle cap. Do not touch the plunger rod as this may cause the prefilled syringe to release medicine prior to injection. You may see a drop of liquid at the tip of the needle. This is normal. Do not remove any air bubbles in the prefilled syringe. Dispose of the needle cap right away in an FDA-cleared sharps disposal container (see Figure N ). Do not re-cap the prefilled syringe as you may stick yourself or damage the needle. Figure N Step 11. Pinch the skin and insert the needle. Hold the barrel of the prefilled syringe in one hand between the thumb and index fingers. Gently pinch a fold of skin at the injection site with one hand. With a quick and dart-like motion, insert the needle completely into the pinched skin at a 45 to 90-degree angle (see Figure O ). Figure O Step 12. Give the injection. Hold the pinch. Slowly push the plunger rod all the way down until the prefilled syringe is empty (see Figure P ). Figure P Step 13. Remove the prefilled syringe. When the prefilled syringe is empty, gently remove the needle from the injection site (see Figure Q ). Figure Q Step 14. Care for the injection site. If any bleeding happens, gently press a cotton ball or gauze on the injection site and hold for several seconds (see Figure R ). Apply an adhesive bandage if needed. Figure R Storing LEROCHOL Store LEROCHOL in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original carton until ready to use and to protect from light. If needed, LEROCHOL may be kept at room temperature between 68°F to 77°F (20°C to 25°C) in the original carton for up to 3 months after being removed from the refrigerator. Throw away LEROCHOL that has been stored at room temperature for more than 3 months. Do not freeze. Do not shake. Keep LEROCHOL and all medicines out of reach of children. Disposing of LEROCHOL Step 15. Dispose of used syringe. Put the used syringe in an FDA-cleared sharps disposal container right away after injection (see Figure S ). Do not re-cap the syringe as you may stick yourself. Do not reuse the syringe. Do not throw away your syringe in your household trash. Do not recycle your used FDA-cleared sharps disposal container. Figure S If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: made of heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. Disposing of sharps disposal containers: When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your FDA-cleared sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. Additional information about your FDA-cleared sharps disposal container. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal Manufactured by: LIB Therapeutics, Inc., 5375 Medpace Way, Cincinnati, OH 45227-1543 Distributed by: LIB Therapeutics, Inc., 5375 Medpace Way, Cincinnati, OH 45227-1543 This Instructions for Use has been approved by the U.S. Food and Drug Administration. Approved: December 2025, Version 0.3 Figure A Figure B Figure C Figure D Figure E Figure F Figure G Figure H Figure I Figure J Figure K Figure L Figure M Figure N Figure O Figure P Figure Q Figure R Figure S"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels. [see Clinical Pharmacology ( 12.3 )] . 12.2 Pharmacodynamics After subcutaneous administration of 300 mg lerodalcibep-liga every month, greater than 90% suppression of PCSK9 occurs within 24 hours after dosing and is maintained throughout the dosing interval, returning toward baseline during the last 7 to 10 days of the monthly dosing period. 12.3 Pharmacokinetics Following a single subcutaneous administration, exposure to lerodalcibep-liga increased in a dose proportional manner over the dose range 75 to 300 mg of lerodalcibep-liga. Lerodalcibep-liga pharmacokinetics were observed at steady state in patients at the approved recommended dosage and are presented as mean (SD), unless otherwise specified. Lerodalcibep-liga maximum concentration (Cmax) is 31.4 (10.2) mcg/mL, and total systemic exposure (AUC0-tau) is 12,600 (5,190) (hrs*mcg/mL) following subcutaneous dose of lerodalcibep-liga 300 mg once every four weeks. Lerodalcibep-liga steady-state is reached following 2 to 3 doses. Lerodalcibep-liga accumulation is approximately 30% at the approved recommended dosage. Absorption The median (min, max) estimated subcutaneous bioavailability of lerodalcibep-liga is 83% (66%, 89%). The median (min, max) time to maximum plasma concentration (Tmax) is 6 days (2, 9 days) at steady state. Distribution Lerodalcibep-liga does not extensively distribute into tissues; the apparent volume of distribution is 5.3 L. Elimination As a protein, lerodalcibep-liga is expected to degrade to small peptides and amino acids. Clearance of free lerodalcibep-liga (CV%) is 0.36 L/day (30%) with an estimated half-life of approximately 10 days. The estimated elimination rate of lerodalcibep-liga (CV%) bound to PCSK9 is 0.47 L/day (22%) which corresponds to a half-life of approximately 1.5 days. Specific Populations No clinically significant differences in the pharmacokinetics of LEROCHOL were observed based on age (21 to 78 years), body weight, sex, race, mild (eGFR 60 to 89 mL/min) or moderate (eGFR 30 to 59 mL/min) renal impairment, or mild (total bilirubin 1.0 to 1.5 upper limit of normal or aspartate aminotransaminase greater than the upper limit of normal) or moderate (total bilirubin 1.5 to 3.0 upper limit of normal) hepatic impairment. The effect of severe renal impairment (eGFR less than 30 mL/min) or severe hepatic impairment on LEROCHOL pharmacokinetics is unknown. Drug Interaction Studies No formal clinical drug interaction studies have been performed. 12.6 Immunogenicity The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of lerodalcibep-liga or of other lerodalcibep products. During the 52-week treatment period in Trial 1 and Trial 2, 15.1% (180/1,195) of LEROCHOL-treated patients at the recommended dosage with evaluable assessments were ADA positive, of whom 22.8% (41/180) had neutralizing antibodies (NAb). During the 24-week treatment period in Trial 3, 11.3% (36/318) of LEROCHOL-treated patients at the recommended dosage with evaluable assessments were ADA positive, of whom 55.6% (20/36) had NAb [see Clinical Studies ( 14 )] . There was no identified clinically significant effect of ADA and NAb on the pharmacokinetics, pharmacodynamics (free PCSK9), safety, or effectiveness (LDL-C) of LEROCHOL over the treatment period of 52 weeks."],"indications_and_usage":["1 INDICATIONS AND USAGE LEROCHOL TM is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LEROCHOL is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise: to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). ( 1 )"],"clinical_studies_table":["
Table 3: Changes in Lipid Parameters in Patients with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD Events on Maximally Tolerated Statin Therapy (Percent Change from Baseline to Week 52 in Trial 1)
Abbreviation: ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; n = number of patients randomly assigned to each treatment group; LS Mean= least-squares mean
a LDL-C, Total Cholesterol, non-HDL-C and ApoB at Week 52 were missing for 7.5% and 10.4% of patients assigned to placebo and LEROCHOL, respectively. Multiple imputation washout model was implemented for imputing missing values at Week 52.
b Least-squares mean from an Analysis of Covariance (ANCOVA) model including treatment as a factor and baseline value as a covariate, assuming unequal variances between groups.
c p-value <0.001 for superiority, controlled for Type I error rate.
d Not controlled for Type I error rate.
Treatment GroupLDL-CaTotal CholesterolaNon-HDL-CaApoBa
Placebo (n = 308) -0.1 -0.2 -0.7 +1
LEROCHOL 300mg (n = 614) -55 -31 -46 -39
Difference from placebo (LS Mean) (95% CI) -55b,c (-59, -51) -31b,d (-33, -28) -45b,d (-48, -41) -40b,d (-44, -37)
","
Table 4: Changes in Lipid Parameters in Patients with Hypercholesterolemia and ASCVD or Increased Risk for ASCVD Events on Maximally Tolerated Statin Therapy (Percent Change from Baseline to Week 52 in Trial 2)
Abbreviation: ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; n = number of patients randomly assigned to each treatment group; LS Mean = least-squares mean
a LDL-C and non-HDL-C at Week 52 were missing for 10.7% and 11.2% of patients assigned to placebo and LEROCHOL, respectively. Total Cholesterol and ApoB at Week 52 were missing for 10.4% and 11.2% of patients assigned to placebo and LEROCHOL, respectively. Multiple imputation washout model was implemented for imputing missing values at Week 52.
b Least-squares mean from an Analysis of Covariance (ANCOVA) model including treatment and CVD status as factors and baseline value as a covariate, assuming unequal variances between groups.
c p-value <0.001 for superiority, controlled for Type I error rate.
d Not controlled for Type I error rate.
Treatment GroupLDL-CaTotal CholesterolaNon-HDL-CaApoBa
Placebo (n = 307) +0.3 +1 +1 +2
LEROCHOL 300mg (n = 615) -49 -28 -41 -36
Difference from placebo (LS Mean) (95% CI) l -50b,c (-54, -45) -29b,d (-32, -26) -42b,d (-46, -38) -38b,d (-42, -35)
","
Table 5: Changes in Lipid Parameters in Patients with HeFH, on Maximally Tolerated Statin Therapy (Percent Change from Baseline to Week 24 in Trial 3)
Abbreviation: ApoB = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; n = number of patients randomly assigned to each treatment group; LS Mean = least-squares mean
a LDL-C, Total Cholesterol and non-HDL-C at Week 24 were missing for 3.1% and 2.8% of patients assigned to placebo and LEROCHOL, respectively. ApoB at Week 24 was missing for 3.1% and 3.1% of patients assigned to placebo and LEROCHOL, respectively. Multiple imputation washout model was implemented for imputing missing values at Week 24.
b Least-squares mean from an Analysis of Covariance (ANCOVA) model including treatment and CVD status as factors and baseline value as a covariate, assuming unequal variances between groups.
c p-value <0.001 for superiority, controlled for Type I error rate.
d Not controlled for Type I error rate.
Treatment GroupLDL-CaTotal CholesterolaNon-HDL-CaApoBa
Placebo (n = 159) + 8 +5 +7 +7
LEROCHOL 300mg (n = 319) -51 -32 -44 -37
Difference from placebo (LS Mean) (95% CI) -59b,c (-66, -52) -37b,d (-41, -32) -51b,d (-57, -45) -44b,d (-49, -39)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with lerodalcibep-liga. The mutagenic potential of lerodalcibep-liga has not been evaluated; however, proteins are not expected to directly interact with DNA or chromosomes. Fertility studies were not performed. However, in a chronic 6-month toxicology study in sexually mature cynomolgus monkeys, no adverse lerodalcibep-liga-related effects on surrogate markers of fertility (reproductive organ histopathology, menstrual cycling, or sperm parameters) were observed when lerodalcibep-liga was administered subcutaneously at 30 and 100 mg/kg once weekly. The highest dose tested corresponds to 138-fold the recommended human dose of 300 mg every month based on serum AUC."],"adverse_reactions_table":["
Table 1: Adverse Reactions Occurring in ≥2% of LEROCHOL-treated Patients with Hypercholesterolemia and > 1% More Frequently than Placebo-treated Patients in Two Pooled 52-Week Trials (Trials 1 and 2)
a Grouped terms composed of several similar terms
Adverse ReactionaLEROCHOL 300 mg (N=1,229) %Placebo (N=612) %
Nasopharyngitis 15 14
Injection site reactions 12 5
Peripheral edema 2 <1
","
Table 2: Adverse Reactions Occurring in ≥2% LEROCHOL-treated Patients with HeFH and >1% More Frequently than Placebo-treated Patients at 24 Weeks (Trial 3)
Adverse ReactionLEROCHOL 300 mg (N=318) %Placebo (N=159) %
a Grouped terms composed of several similar terms
Injection site reactionsa18 3
Nasopharyngitisa13 9
Diarrhea 3 1
Nausea 2 0
Peripheral edemaa2 <1
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient and/or caregiver to read the FDA-Approved Patient Labeling (Patient Information and Instructions for Use). Administration Provide guidance to patients and caregivers on proper subcutaneous injection technique and how to use the prefilled syringe correctly. Inform patients that the prefilled syringe should be allowed to warm to room temperature for 30 minutes prior to use, if refrigerated [see Dosage and Administration ( 2.3 )]. Manufactured by: LIB Therapeutics, Inc. 5375 Medpace Way Cincinnati, OH 45227-1543 Version 0.5"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dosage of LEROCHOL is 300 mg administered subcutaneously once monthly. ( 2.1 ) Inject LEROCHOL subcutaneously into the abdomen or thigh. A caregiver or healthcare professional can administer into the upper arm. ( 2.2 ) Refer to the Instructions for Use for administration of prefilled syringe. ( 2.2 ) 2.1 Recommended Dosage The recommended dosage of LEROCHOL is 300 mg once monthly administered subcutaneously. Assess LDL-C when clinically indicated. The LDL-lowering effect of LEROCHOL may be measured as early as 4 weeks after initiation and, provided monthly dosing is continued, anytime thereafter without regard to timing of the dose. 2.2 Recommendations Regarding Missed Dose(s) If a dose is missed by: Less than 7 days, instruct the patient to administer LEROCHOL as soon as possible and resume the patient's original monthly dosage schedule. Seven (7) or more days, instruct the patient to administer LEROCHOL as soon as possible and start a new monthly dosage schedule based on this date. 2.3 Important Administration Instructions Train patients and/or their caregivers on how to prepare and administer LEROCHOL, according to the Instructions for Use, and instruct them to read and follow the Instructions for Use each time they use LEROCHOL. Prior to use, allow LEROCHOL to warm to room temperature up to 25°C (77°F) for at least 30 minutes if LEROCHOL has been refrigerated [see How Supplied/Storage and Handling ( 16 )] . Visually inspect LEROCHOL prior to administration. LEROCHOL is a clear to slightly opalescent, brownish-yellow to amber solution. Do not use if the solution is cloudy or contains particles. Inject LEROCHOL subcutaneously into the abdomen or the upper front thighs. If injected by a healthcare professional or caregiver, the back of the upper arms can also be a site of injection [see Instructions for Use] . Do not inject in an area of the skin that is tender, bruised, red, or indurated. Rotate injection sites for each administration. To administer the full 300 mg dose, push plunger down until the syringe is empty before removing from the injection site."],"spl_product_data_elements":["LEROCHOL lerodalcibep-liga lerodalcibep lerodalcibep histidine histidine monohydrochloride polysorbate 80 sodium chloride Water"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 300 mg/1.2 mL (250 mg/mL) of clear to slightly opalescent, brownish-yellow to amber solution in a single-dose prefilled syringe. Injection: 300 mg/1.2 mL (250 mg/mL) solution in a single-dose prefilled syringe. ( 3 )"],"instructions_for_use_table":["
Figure EFigure FFigure GFigure H
"],"spl_patient_package_insert":["This Patient Package Insert has been approved by the U.S. Food and Drug Administration. 12/2025 Patient Information LEROCHOL TM (leer-O-call) (lerodalcibep-liga) injection, for subcutaneous use What is LEROCHOL? LEROCHOL is an injectable prescription medicine used along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) or bad cholesterol in adults with high blood cholesterol levels called hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH). It is not known if LEROCHOL is safe and effective in children. What should I tell my healthcare provider before using LEROCHOL? Before you start using LEROCHOL, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. It is not known if LEROCHOL will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking LEROCHOL. are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take LEROCHOL or breastfeed. You should not do both without talking to your healthcare provider first. Tell your healthcare provider or pharmacist about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I use LEROCHOL? See the detailed Instructions for Use that comes with this Patient Information about the right way to prepare and give your LEROCHOL injections. Use LEROCHOL exactly as your healthcare provider tells you to use it. LEROCHOL comes as a single-dose (1 time) prefilled syringe. If your healthcare provider decides that you or a caregiver can give the injections of LEROCHOL, you or your caregiver should receive training on the right way to prepare and give LEROCHOL. Do not try to inject LEROCHOL until you have been shown the right way by your healthcare provider or nurse. LEROCHOL is injected under the skin (subcutaneously) 1 time every month. LEROCHOL can be self-injected in the stomach area, at least 2 inches away from the belly button or upper front of the legs (thighs). LEROCHOL can be injected by a caregiver or healthcare provider in the back of the upper arm. Do not choose an area where the skin is tender, bruised, red, or hard. Do not inject LEROCHOL together with other injectable medicines at the same injection site. Always check the label of your syringe to make sure you have the correct medicine. If you forget to use LEROCHOL or are not able to take the dose on your regular schedule, inject your missed dose as soon as you remember if it has been less than 7 days of the missed dose and continue the original monthly dosage schedule. If it is 7 or more days from the missed dose, inject the dose and start a new monthly schedule using the date LEROCHOL was taken. If you are not sure when to re-start LEROCHOL, ask your healthcare provider or pharmacist. If you use more LEROCHOL than you should, talk to your healthcare provider or pharmacist. Do not stop using LEROCHOL without talking with your healthcare provider. If you stop using LEROCHOL, your cholesterol levels can increase. What are the possible side effects of LEROCHOL? The common side effects of LEROCHOL include: redness, itching, swelling, pain, bruising or tenderness at the injection site runny or stuffy nose, sore throat (nasopharyngitis) diarrhea nausea swelling in arms, hands, legs, or feet (peripheral edema) Tell your healthcare provider if you have any side effect that bothers you or that does not go away. Ask your healthcare provider or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800- FDA-1088. How should I store LEROCHOL? Store LEROCHOL in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original carton until ready to use and to protect from light. If needed, LEROCHOL may be kept at room temperature between 68°F to 77°F (20°C to 25°C) in the original carton for up to 3 months after being removed from the refrigerator. Throw away LEROCHOL that has been stored at room temperature for more than 3 months. Do not freeze. Do not shake. Keep LEROCHOL and all medicines out of reach of children. General information about the safe and effective use of LEROCHOL. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LEROCHOL for a condition for which it was not prescribed. Do not give LEROCHOL to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about LEROCHOL that is written for health professionals. What are the ingredients in LEROCHOL? Active ingredient: lerodalcibep-liga Inactive ingredients: histidine, L-histidine monohydrochloride, polysorbate 80, sodium chloride, and Water for Injection, USP. Manufactured by: LIB Therapeutics, Inc. 5375 Medpace Way, Cincinnati, OH 45227-1543, U.S. License # 2352; LEROCHOL is a registered trademark of LIB Therapeutics, Inc. / ©2024 LIB Therapeutics, Inc. All rights reserved. Version 0.3 For more information about LEROCHOL, go to www.LEROCHOL.com or call 1-877-2-LEROCHOL (1-877-253-7624)."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Discontinue LEROCHOL when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. LEROCHOL increases LDL-C uptake and lowers LDL-C levels in the circulation, thus decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, LEROCHOL may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology ( 12.1 )]. In addition, treatment of hypercholesterolemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia for most patients. Available data from clinical trials on LEROCHOL use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, there were no adverse developmental effects observed when pregnant monkeys were administered lerodalcibep-liga subcutaneously during organogenesis and through to parturition at doses up to 100 mg/kg/week [up to 119-fold the exposure at the maximum recommended human dose (MRHD) of 300 mg every month]. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In cynomolgus monkeys, no effects on embryo-fetal or postnatal development (up to 6 months of age) were observed when lerodalcibep-liga was dosed during organogenesis and through parturition at 30 and 100 mg/kg subcutaneously once weekly (exposures up to 119-fold the MRHD by AUC). An assessment of immune function in the infants showed no treatment-related adverse effects. Measurable lerodalcibep-liga serum concentrations were observed in the infant monkeys with infant serum concentrations approximately 2 to 7% of maternal serum concentrations on postnatal days 14, 21 and 28, indicating that lerodalcibep-liga has the potential to be transmitted from the mother to the developing fetus. 8.2 Lactation Risk Summary There are no data on the presence of lerodalcebip-liga in human milk, the effects on the breastfed infant, or the effects on milk production. In animal reproduction studies, lerodalcibep-liga was present in the milk of lactating monkeys (see Data ). When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for LEROCHOL and any potential adverse effects on the breastfed infant from LEROCHOL or from the underlying maternal condition. Data Low concentrations of lerodalcibep-liga were measured in milk samples collected from monkeys on post-partum day (PPD) 7 and PPD 14, when lerodalcibep-liga was dosed during organogenesis through parturition at 30 and 100 mg/kg subcutaneously once weekly (exposures up to 119-fold the MRHD by AUC). There is no information regarding whether lerodalcibep-liga ingested with milk transfers to neonatal or infant monkey circulation. 8.4 Pediatric Use The safety and effectiveness of LEROCHOL in pediatric patients have not been established. Clinical trials of LEROCHOL in pediatric patients with HeFH have not been conducted. Effectiveness of LEROCHOL was not demonstrated in a 24-week, randomized, open-label, active-controlled trial (NCT04034485) in 19 pediatric patients aged 10 to 17 years with homozygous familial hypercholesterolemia (HoFH). 8.5 Geriatric Use Of the 1,631 patients treated with LEROCHOL 300 mg in clinical trials, 687 (42%) patients were 65 years of age and older, while 198 (12%) patients were 75 years of age or older. No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger adult patients. 8.6 Renal Impairment No dose adjustment is necessary in patients with mild to moderate renal impairment [estimated glomerular filtration rate (eGFR) ≥30 to <90 mL/min] [see Clinical Pharmacology ( 12.3 )] . LEROCHOL has not been studied in patients with severe renal impairment (eGFR < 30 mL/min) or end-stage renal disease. 8.7 Hepatic Impairment No dose adjustment is necessary in patients with mild (total bilirubin 1.0 to 1.5 upper limit of normal or aspartate aminotransaminase > upper limit of normal) or moderate (total bilirubin 1.5 to 3.0 upper limit of normal) hepatic impairment [see Clinical Pharmacology ( 12.3 )]. LEROCHOL has not been studied in patients with severe hepatic impairment."],"spl_patient_package_insert_table":["
This Patient Package Insert has been approved by the U.S. Food and Drug Administration. 12/2025
Patient Information LEROCHOLTM (leer-O-call) (lerodalcibep-liga) injection, for subcutaneous use
What is LEROCHOL? LEROCHOL is an injectable prescription medicine used along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) or bad cholesterol in adults with high blood cholesterol levels called hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH). It is not known if LEROCHOL is safe and effective in children.
What should I tell my healthcare provider before using LEROCHOL? Before you start using LEROCHOL, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant. It is not known if LEROCHOL will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking LEROCHOL. are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take LEROCHOL or breastfeed. You should not do both without talking to your healthcare provider first.
Tell your healthcare provider or pharmacist about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use LEROCHOL? See the detailed Instructions for Use that comes with this Patient Information about the right way to prepare and give your LEROCHOL injections.Use LEROCHOL exactly as your healthcare provider tells you to use it. LEROCHOL comes as a single-dose (1 time) prefilled syringe. If your healthcare provider decides that you or a caregiver can give the injections of LEROCHOL, you or your caregiver should receive training on the right way to prepare and give LEROCHOL. Do not try to inject LEROCHOL until you have been shown the right way by your healthcare provider or nurse. LEROCHOL is injected under the skin (subcutaneously) 1 time every month. LEROCHOL can be self-injected in the stomach area, at least 2 inches away from the belly button or upper front of the legs (thighs). LEROCHOL can be injected by a caregiver or healthcare provider in the back of the upper arm. Do not choose an area where the skin is tender, bruised, red, or hard. Do not inject LEROCHOL together with other injectable medicines at the same injection site. Always check the label of your syringe to make sure you have the correct medicine. If you forget to use LEROCHOL or are not able to take the dose on your regular schedule, inject your missed dose as soon as you remember if it has been less than 7 days of the missed dose and continue the original monthly dosage schedule. If it is 7 or more days from the missed dose, inject the dose and start a new monthly schedule using the date LEROCHOL was taken. If you are not sure when to re-start LEROCHOL, ask your healthcare provider or pharmacist. If you use more LEROCHOL than you should, talk to your healthcare provider or pharmacist. Do not stop using LEROCHOL without talking with your healthcare provider. If you stop using LEROCHOL, your cholesterol levels can increase.
What are the possible side effects of LEROCHOL? The common side effects of LEROCHOL include: redness, itching, swelling, pain, bruising or tenderness at the injection site runny or stuffy nose, sore throat (nasopharyngitis) diarrhea nausea swelling in arms, hands, legs, or feet (peripheral edema)
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. Ask your healthcare provider or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800- FDA-1088.
How should I store LEROCHOL? Store LEROCHOL in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original carton until ready to use and to protect from light. If needed, LEROCHOL may be kept at room temperature between 68°F to 77°F (20°C to 25°C) in the original carton for up to 3 months after being removed from the refrigerator. Throw away LEROCHOL that has been stored at room temperature for more than 3 months. Do not freeze. Do not shake.
Keep LEROCHOL and all medicines out of reach of children.
General information about the safe and effective use of LEROCHOL. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LEROCHOL for a condition for which it was not prescribed. Do not give LEROCHOL to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about LEROCHOL that is written for health professionals.
What are the ingredients in LEROCHOL? Active ingredient: lerodalcibep-liga Inactive ingredients: histidine, L-histidine monohydrochloride, polysorbate 80, sodium chloride, and Water for Injection, USP.
Manufactured by: LIB Therapeutics, Inc. 5375 Medpace Way, Cincinnati, OH 45227-1543, U.S. License # 2352; LEROCHOL is a registered trademark of LIB Therapeutics, Inc. / ©2024 LIB Therapeutics, Inc. All rights reserved. Version 0.3 For more information about LEROCHOL, go to www.LEROCHOL.com or call 1-877-2-LEROCHOL (1-877-253-7624).
"],"package_label_principal_display_panel":["Principal Display Panel – 300 mg/1.2 mL Carton Label NDC: 84685-300-01 Rx Only LEROCHOL™ (lerodalcibep-liga) Injection 300 mg/1.2 mL (250 mg/mL) 1 Single-dose Prefilled Syringe 300 mg/1.2 mL (250 mg/mL) For Subcutaneous Injection Single-dose Prefilled Syringe Discard unused portion. Sterile Solution – No Preservative Keep out of the sight and reach of children LIB THERAPEUTICS Principal Display Panel – 300 mg/1.2 mL Carton Label","Principal Display Panel – 300 mg/1.2 mL Tray Label NDC: 84685-300-01 LEROCHOL™ (lerodalcibep-liga) Injection 300 mg/1.2 mL (250 mg/mL) Rx Only 1 Single-dose Prefilled Syringe 300 mg/1.2 mL (250 mg/mL) For Subcutaneous Injection Single-dose Prefilled Syringe Discard unused portion. Sterile Solution – No Preservative Principal Display Panel – 300 mg/1.2 mL Tray Label","Principal Display Panel – 300 mg/1.2 mL Prefilled Syringe Label NDC: 84685-300-01 Rx Only LEROCHOL™ (lerodalcibep-liga) Injection 300 mg/1.2 mL (250 mg/mL) For Subcutaneous Injection Single-dose Prefilled Syringe Discard unused portion. Sterile Solution – No Preservative Principal Display Panel – 300 mg/1.2 mL Prefilled Syringe Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been performed with lerodalcibep-liga. The mutagenic potential of lerodalcibep-liga has not been evaluated; however, proteins are not expected to directly interact with DNA or chromosomes. Fertility studies were not performed. However, in a chronic 6-month toxicology study in sexually mature cynomolgus monkeys, no adverse lerodalcibep-liga-related effects on surrogate markers of fertility (reproductive organ histopathology, menstrual cycling, or sperm parameters) were observed when lerodalcibep-liga was administered subcutaneously at 30 and 100 mg/kg once weekly. The highest dose tested corresponds to 138-fold the recommended human dose of 300 mg every month based on serum AUC."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Subcutaneous","category":"route"},{"label":"Injectable","category":"form"},{"label":"Active","category":"status"},{"label":"hypercholesterolemia","category":"indication"},{"label":"heterozygous familial hypercholesterolemia (HeFH)","category":"indication"},{"label":"Lib Therapeutics, Inc.","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"15%","severity":"common","_validated":true},{"effect":"Injection site reactions","drugRate":"12%","severity":"common","_validated":true},{"effect":"Peripheral edema","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Diarrhea","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"2%","severity":"mild","_validated":true}],"contraindications":[],"specialPopulations":{"Pregnancy":"Discontinue LEROCHOL when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. LEROCHOL increases LDL-C uptake and lowers LDL-C levels in the circulation, thus decreasing cholesterol and possibly other biologically active substances derived from cholesterol; therefore, LEROCHOL may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology ( 12.1 )]. In addition, treatment of hypercholesterolemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia for most patients. Available data from clinical trials on LEROCHOL use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, there were no adverse developmental effects observed when pregnant monkeys were administered lerodalcibep-liga subcutaneously during organogenesis and through to parturition at doses up to 100 mg/kg/week [up to 119-fold the exposure at the maximum recommended human dose (MRHD) of 300 mg every month]. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, ","Geriatric use":"Of the 1,631 patients treated with LEROCHOL 300 mg in clinical trials, 687 (42%) patients were 65 years of age and older, while 198 (12%) patients were 75 years of age or older. No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger adult patients.","Paediatric use":"The safety and effectiveness of LEROCHOL in pediatric patients have not been established. Clinical trials of LEROCHOL in pediatric patients with HeFH have not been conducted. Effectiveness of LEROCHOL was not demonstrated in a 24-week, randomized, open-label, active-controlled trial (NCT04034485) in 19 pediatric patients aged 10 to 17 years with homozygous familial hypercholesterolemia (HoFH)."}},"trials":[],"aliases":[],"company":"Lib Therapeutics, Inc.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LERODALCIBEP","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:15:56.226080+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:16:01.709346+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:15:50.750320+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LERODALCIBEP","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:16:02.006899+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:15:50.314245+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:15:50.314272+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Subtilisin/kexin type 9 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:03.059763+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650405/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:02.711907+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761427","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:15:50.314276+00:00"}},"allNames":"lerochol","offLabel":[],"synonyms":["Lerochol"],"timeline":[{"date":"20251212","type":"positive","source":"OpenFDA","milestone":"FDA approval (Lib Therapeutics, Inc.)"}],"approvals":[{"date":"20251212","orphan":false,"company":"LIB THERAPEUTICS, INC.","regulator":"FDA"}],"brandName":"Lerochol","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels. [see Clinical Pharmacology ( 12.3 )] .","oneSentence":"Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels.","technicalDetail":"Lerodalcibep is a small molecule that binds to a specific protein, thereby modulating the activity of a key enzyme involved in cholesterol metabolism. This results in increased clearance of low-density lipoprotein (LDL) cholesterol from the bloodstream, leading to decreased cholesterol levels."},"commercial":{"launchDate":"2025","_launchSource":"OpenFDA (20251212, LIB THERAPEUTICS, INC.)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"LERODALCIBEP\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"LERODALCIBEP\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=lerodalcibep","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lerodalcibep","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:35:27.637684","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:05.916280+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"lerodalcibep","indications":{"approved":[{"name":"hypercholesterolemia","source":"OpenFDA Label","regulator":"FDA"},{"name":"heterozygous familial hypercholesterolemia (HeFH)","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07102511","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH","status":"NOT_YET_RECRUITING","sponsor":"LIB Therapeutics LLC","startDate":"2025-09-01","conditions":["Familial Hypercholesterolemia - Heterozygous"],"enrollment":150,"completionDate":"2027-06-30"},{"nctId":"NCT06504043","phase":"PHASE1","title":"A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants","status":"ENROLLING_BY_INVITATION","sponsor":"Hasten Biopharmaceutical Co., Ltd.","startDate":"2024-09-17","conditions":["Hypercholesterolemia","Healthy Volunteers","LDL-Cholesterol"],"enrollment":30,"completionDate":"2025-03-31"},{"nctId":"NCT06568471","phase":"PHASE3","title":"A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia","status":"RECRUITING","sponsor":"Hasten Biopharmaceutical Co., Ltd.","startDate":"2024-11-16","conditions":["Hypercholesterolemia","Dyslipidemias","Primary Hypercholesterolemia","Heterozygous Familial Hypercholesterolemia","Hyperlipidemia; Mixed","Metabolic Disease","ASCVD"],"enrollment":210,"completionDate":"2026-05"},{"nctId":"NCT05004675","phase":"PHASE3","title":"Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2022-06-20","conditions":["Hypercholesterolemia","Atherosclerotic Ischemic Disease"],"enrollment":166,"completionDate":"2024-10-15"},{"nctId":"NCT04798430","phase":"PHASE3","title":"Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction","status":"ENROLLING_BY_INVITATION","sponsor":"LIB Therapeutics LLC","startDate":"2020-12-03","conditions":["Cardiovascular Disease With Mention of Arteriosclerosis","Elevated Cholesterol","Familial Hypercholesterolemia"],"enrollment":2000,"completionDate":"2025-12-31"},{"nctId":"NCT04797247","phase":"PHASE3","title":"Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction","status":"UNKNOWN","sponsor":"LIB Therapeutics LLC","isPivotal":true,"startDate":"2021-04-22","conditions":["Cardiovascular Diseases","Hyper-LDL-cholesterolemia"],"enrollment":900,"completionDate":"2024-02-28"},{"nctId":"NCT04806893","phase":"PHASE3","title":"Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction","status":"UNKNOWN","sponsor":"LIB Therapeutics LLC","isPivotal":true,"startDate":"2021-04-22","conditions":["Cardiovascular Risk Factor","Cardiovascular Diseases","Cardiovascular Stroke","Hypercholesterolemia"],"enrollment":900,"completionDate":"2024-02-28"},{"nctId":"NCT04797104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","isPivotal":true,"startDate":"2021-04-22","conditions":["Heterozygous Familial Hypercholesterolemia"],"enrollment":478,"completionDate":"2023-12-05"},{"nctId":"NCT04790513","phase":"PHASE3","title":"Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2021-04-22","conditions":["Hypercholesterolemia","Cardiovascular Diseases"],"enrollment":204,"completionDate":"2022-12-31"},{"nctId":"NCT04034485","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2019-12-07","conditions":["Homozygous Familial Hypercholesterolemia"],"enrollment":65,"completionDate":"2023-01-30"},{"nctId":"NCT05234775","phase":"PHASE3","title":"Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2022-01-28","conditions":["Hypercholesterolemia"],"enrollment":22,"completionDate":"2022-07-11"},{"nctId":"NCT03847974","phase":"PHASE2","title":"Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2019-02-14","conditions":["Hypercholesterolemia"],"enrollment":32,"completionDate":"2020-08-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT04797247","NCT04806893","NCT04797104"],"administration":{"route":"Subcutaneous","formulation":"Injectable","formulations":[{"form":"INJECTABLE","route":"SUBCUTANEOUS","productName":""}]},"crossReferences":{"UNII":"1PHP3QG5PZ","RXCUI":"2729467,2729474","SPL_ID":"593f8f9d-235b-4753-8843-4d7e6d6d5365","chemblId":"CHEMBL4650405"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2025-","companyName":"Lib Therapeutics, Inc.","relationship":"Original Developer"}],"pharmacokinetics":{"source":"OpenFDA Label","halfLife":"10 days"},"publicationCount":17,"therapeuticAreas":["Metabolic"],"applicationNumber":"BLA761427","biosimilarFilings":[],"originalDeveloper":"Lib Therapeutics, Inc.","recentPublications":[{"date":"2026 Mar 2","pmid":"41771767","title":"Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review.","journal":"British journal of pharmacology"},{"date":"2006","pmid":"41730058","title":"Lerodalcibep.","journal":""},{"date":"2026 Mar","pmid":"41616414","title":"From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies.","journal":"Pharmacological reviews"},{"date":"2026 Mar","pmid":"41550128","title":"Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis.","journal":"International journal of cardiology. Cardiovascular risk and prevention"},{"date":"2025 Sep","pmid":"41089781","title":"Lerodalcibep: Another Crucial Addition to the Dyslipidaemia Arsenal.","journal":"Reviews in cardiovascular medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Lib Therapeutics, Inc.","companyId":"lib-therapeutics-inc","modality":"Recombinant protein","firstApprovalDate":"2025","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-12-12T00:00:00.000Z","mah":"LIB THERAPEUTICS, INC.","brand_name_local":null,"application_number":"BLA761427"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"LIB THERAPEUTICS, INC.","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"LIB THERAPEUTICS, INC.","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"LIB THERAPEUTICS, INC.","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"LIB THERAPEUTICS, INC.","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"LIB THERAPEUTICS, INC.","brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"LIB THERAPEUTICS, INC.","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:05.916280+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}